96 related articles for article (PubMed ID: 25948159)
1. Histologic and Immunohistochemical Alterations Associated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy.
Wagner P; Boone B; Ramalingam L; Jones H; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh H; Choudry H; Bartlett D
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S588-95. PubMed ID: 25948159
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for managing peritoneal carcinomatosis from endometrial carcinoma: a single-center experience of 6 cases.
Abu-Zaid A; Azzam AZ; AlOmar O; Salem H; Amin T; Al-Badawi IA
Ann Saudi Med; 2014; 34(2):159-66. PubMed ID: 24894786
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study.
Leimkühler M; Hemmer PHJ; Reyners AKL; de Groot DJA; van Ginkel RJ; Been LB; de Bock GH; van Leeuwen BL
World J Surg Oncol; 2019 Jan; 17(1):14. PubMed ID: 30635070
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative.
Fackche NT; Schmocker RK; Nudotor R; Kubi B; Cloyd JM; Grotz TE; Fournier KF; Dineen SP; Veerapong J; Baumgartner JM; Clarke CN; Patel SH; Wilson GC; Lambert LA; Pokrzywa C; Abbott DE; Lee B; Staley CA; Zaidi MY; Johnston FM; Greer JB
Ann Surg Oncol; 2024 May; 31(5):3314-3324. PubMed ID: 38310181
[TBL] [Abstract][Full Text] [Related]
5. Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy.
Kleber J; Yang Zhou J; Weber F; Bitterer F; Hauer P; Kupke P; Kronenberg K; Geissler EK; Schlitt HJ; Hornung M; Hutchinson JA; Werner JM
Cancer Immunol Immunother; 2023 Nov; 72(11):3867-3873. PubMed ID: 37580610
[TBL] [Abstract][Full Text] [Related]
6. Does Hospital Operative Volume Influence the Outcomes of Patients After Heated Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis?
Chatani PD; Manzella A; Gribkova YY; Ecker BL; Beninato T; Kennedy T; Pitt HA; Alexander HR
Ann Surg Oncol; 2024 Feb; 31(2):1049-1057. PubMed ID: 37906385
[TBL] [Abstract][Full Text] [Related]
7. Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery.
Dhiman A; Kothary V; Witmer HDD; Bregio C; Sood D; Ong CT; Polite B; Eng OS; Shergill A; Turaga KK
Ann Surg; 2023 Dec; 278(6):925-931. PubMed ID: 36994703
[TBL] [Abstract][Full Text] [Related]
8. Doublet vs. Triplet Systemic Chemotherapy for High Grade Appendiceal Adenocarcinoma with Peritoneal Metastases.
Morgan RB; Dhiman A; Kim AC; Shergill A; Polite B; Turaga KK; Eng OS
J Gastrointest Surg; 2023 Nov; 27(11):2560-2562. PubMed ID: 37308734
[No Abstract] [Full Text] [Related]
9. Invited commentary: Extremely high peritoneal cancer index in colorectal peritoneal metastases demonstrates safety and overall survival benefit in selected patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
Pocard M
World J Surg; 2024 Apr; 48(4):879-880. PubMed ID: 38447984
[No Abstract] [Full Text] [Related]
10. Factors associated with stoma closure after cytoreductive surgery.
Maspero M; Yilmaz S; Joyce D; DeBernardo R; Liska D; Gorgun E; Steele SR; Valente MA
Am J Surg; 2024 Apr; 230():47-51. PubMed ID: 38042719
[TBL] [Abstract][Full Text] [Related]
11. Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms.
White MG; Bhutiani N; Helmink BA; Taggart M; Foo WC; Mansfield PF; Fournier KF; Scally CP
Ann Surg Oncol; 2023 Dec; 30(13):8138-8143. PubMed ID: 37702905
[TBL] [Abstract][Full Text] [Related]
12. Incomplete cytoreductive surgery for appendiceal and colorectal peritoneal carcinomatosis: Characteristics and outcomes of an overlooked group.
Goffredo P; Aguirre N; Mohamed M; Kleiman DA; Cercek A; Joshua Smith J; Paty PB; Weiser M; Garcia-Aguilar J; Nash GM
J Surg Oncol; 2023 May; 127(6):1028-1034. PubMed ID: 36862078
[TBL] [Abstract][Full Text] [Related]
13. Successful Implementation of HITOC and HIPEC in the Management of Advanced Ovarian Carcinoma with Pleural and Peritoneal Carcinomatosis.
Moldovan B; Saon CT; Adam II; Pisica RM; Silaghi VT; Untaru V; Stoica D; Crisan M; Popianas A; Pescaru F; Zolog A; Vecerzan L
Diagnostics (Basel); 2024 Feb; 14(5):. PubMed ID: 38472928
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a desirable dose using neutral argon plasma to eradicate miliary peritoneal implants: A phase I/II controlled trial.
Pontes-García A; Martínez-López A; Rodríguez-Ortiz L; Valenzuela-Molina F; Rufián-Andújar B; Sánchez-Hidalgo JM; Casado-Adam A; Gordon-Suarez A; Rufián-Peña S; Vázquez-Borrego MC; Romero-Ruiz A; Arjona-Sánchez A
Eur J Surg Oncol; 2023 Sep; 49(9):106978. PubMed ID: 37460370
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Early Recurrence Following CRS/HIPEC in Patients With Disseminated Appendiceal Cancer.
SenthilKumar G; Merrill J; Maduekwe UN; Cloyd JM; Fournier K; Abbott DE; Zafar N; Patel S; Johnston F; Dineen S; Baumgartner J; Grotz TE; Maithel SK; Raoof M; Lambert L; Hendrix R; Kothari AN
J Surg Res; 2023 Dec; 292():275-288. PubMed ID: 37666090
[TBL] [Abstract][Full Text] [Related]
16. Editorial: Management of peritoneal surface malignancies. (cytoreductive surgery, HIPEC, PIPAC, and beyond).
Souadka A; Bakrin N
Front Oncol; 2024; 14():1340737. PubMed ID: 38532932
[No Abstract] [Full Text] [Related]
17. Metastasis-associated fibroblasts in peritoneal surface malignancies.
Ramos C; Gerakopoulos V; Oehler R
Br J Cancer; 2024 May; ():. PubMed ID: 38783165
[TBL] [Abstract][Full Text] [Related]
18. Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial.
Iavazzo C; Gkegkes ID; Spiliotis J
Pleura Peritoneum; 2024 Mar; 9(1):45-46. PubMed ID: 38558873
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Integrating Multimodal Pain Management Protocols into ERAS for Patients Undergoing CRS-HIPEC.
Yue T; Sun B; Lee B
Ann Surg Oncol; 2024 Mar; ():. PubMed ID: 38483646
[No Abstract] [Full Text] [Related]
20. ASO Visual Abstract: Negative Pressure Wound Therapy to Reduce Surgical Site Infections After CRS/HIPEC.
Nabata KJ; Rai S; Zhao D; MacNeill AJ; Hamilton TD
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38796588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
